Todos Medical Enters Into a $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory

What To Know

  • , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer's disease, today announced that it has entered into a sales agreement with a Texas-based laboratory to supply it with the necessary testing equipment and supplies for an initial amount in excess of $1.
  • “The recent COVID-19 automated instrument and consumable supply agreement between Todos Medical and this Texas-based laboratory is an example of Todos' ongoing commitment to support the operations of America's network of frontline laboratories as they work to meet the needs of the American public,” said Andrew Blumenthal, Todos Medical Vice President of Business Development.

Todos Medical Ltd., an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a sales agreement with a Texas-based laboratory to supply it with the necessary testing equipment and supplies for an initial amount in excess of $1.28 million.

Todos Medical will be supplying automated extraction machines, liquid handlers and PCR machines. The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.

“The recent COVID-19 automated instrument and consumable supply agreement between Todos Medical and this Texas-based laboratory is an example of Todos’ ongoing commitment to support the operations of America’s network of frontline laboratories as they work to meet the needs of the American public,” said Andrew Blumenthal, Todos Medical Vice President of Business Development.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy